A Review of Applications of Metabolomics in Cancer

Beger, Richard D.

doi:10.3390/metabo3030552

Cited by 244 publications

(198 citation statements)

References 147 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…In this way, it will be possible to monitor and discover metabolic changes related to disease onset or therapeutic interventions. Those techniques have been already applied to chronic renal diseases, hepatocellular carcinoma and colorectal cancers 185 as well as to oral cancer and periodontal diseases.…”

Section: Metabolomicsmentioning

confidence: 99%

Saliva diagnostics – Current views and directions

Kaczor‐Urbanowicz

Carreras‐Presas

Aro

et al. 2016

Exp Biol Med (Maywood)

358

271

View full text Add to dashboard Cite

The purpose of this mini-review is to make an update about the present and future applications of saliva as a diagnostic biofluid in many fields of science such as dentistry, medicine and pharmacotherapy. Using saliva as a fluid for diagnostic purposes would be a huge breakthrough for both patients and healthcare providers since saliva collection is easy, non-invasive and inexpensive. We will go through the current main diagnostic applications of saliva, and provide a highlight on the emerging, newly developing technologies and tools for cancer screening, detection and monitoring. AbstractIn this review, we provide an update on the current and future applications of saliva for diagnostic purposes. There are many advantages of using saliva as a biofluid. Its collection is fast, easy, inexpensive, and non-invasive. In addition, saliva, as a ''mirror of the body,'' can reflect the physiological and pathological state of the body. Therefore, it serves as a diagnostic and monitoring tool in many fields of science such as medicine, dentistry, and pharmacotherapy. Introduced in 2008, the term ''Salivaomics'' aimed to highlight the rapid development of knowledge about various ''omics'' constituents of saliva, including: proteome, transcriptome, micro-RNA, metabolome, and microbiome. In the last few years, researchers have developed new technologies and validated a wide range of salivary biomarkers that will soon make the use of saliva a clinical reality. However, a great need still exists for convenient and accurate point-of-care devices that can serve as a non-invasive diagnostic tool. In addition, there is an urgent need to decipher the scientific rationale and mechanisms that convey systemic diseases to saliva. Another promising technology called liquid biopsy enables detection of circulating tumor cells (CTCs) and fragments of tumor DNA in saliva, thus enabling non-invasive early detection of various cancers. The newly developed technology-electric field-induced release and measurement (EFIRM) provides near perfect detection of actionable mutations in lung cancer patients. These recent advances widened the salivary diagnostic approach from the oral cavity to the whole physiological system, and thus point towards a promising future of salivary diagnostics for personalized individual medicine applications including clinical decisions and post-treatment outcome predictions.

show abstract

Section: Metabolomicsmentioning

confidence: 99%

Saliva diagnostics – Current views and directions

Kaczor‐Urbanowicz

Carreras‐Presas

Aro

et al. 2016

Exp Biol Med (Maywood)

358

271

View full text Add to dashboard Cite

show abstract

“…Thus, potential biomarkers that can address these issues relating to drug resistance and can predict the response of a patient to pemetrexed plus platinum doublet therapy are needed. Author Manuscript Published OnlineFirst on February 6, 2018; DOI: 10.1158/1078-0432.CCR- Metabolomics is an -omics technology that provides information that complements the genomic and proteomic profile of a sample (14). Metabolites are stable in serum and can be quantified, which presents an opportunity to establish a non-invasive approach for monitoring disease status and exploring biomarkers to predict the efficacy of anticancer therapies (15).…”

Section: Introductionmentioning

confidence: 99%

Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling

Tian

Wang

Liu

et al. 2018

Clinical Cancer Research

View full text Add to dashboard Cite

In clinical practice, there are currently no validated biomarkers that can, prior to treatment, reliably indicate the intrinsically sensitive or resistant features of a non-squamous NSCLC patient to pemetrexed plus platinum doublet chemotherapy. In this study, we investigated the metabolic characteristics of a large cohort of pre-chemotherapeutic serum samples (354 cases) and found tight associations between small metabolite subsets and the responses of patients to this cytotoxic drug combination. We developed an effective discriminant model employing a seven-metabolite panel (Hypotaurine, Uridine, Dodecanoylcarnitine, Choline, Dimethylglycine, Niacinamide, L-palmitoylcarnitine) that can predict the efficacy of this chemotherapeutic regimens, prior to treatment, with a sensitivity of 90.8% and specificity of 79.5%. We also identified three one-carbon metabolism-involved metabolites including choline, betaine and DMG that are potentially associated with drug resistance to pemetrexed. This serum-based biomarker study can be easily applied in clinical practice and personalize treatment decisions. Conclusion:This study developed an effective and convenient discriminant model that can accurately predict the efficacy and survival outcomes of pemetrexed plus platinum doublet chemotherapy prior to treatment delivery.

show abstract

“…Recent research in this field has focused on metabolomics profiling for biomarkers discovery using different biological samples (tissue, urine, exhaled breath condensate, or plasma) [26]. However, as mentioned before, the complexity of serum/plasma and urine matrices is a factor to be considered in the search for biomarkers since other pathological conditions could interfere, particularly when a panel of markers formed by metabolites involved in primary metabolism is found.…”

Section: Introductionmentioning

confidence: 98%

“…This is the case with amino acids or compounds involved in energy metabolism (glycolysis or Krebs' cycle) [27] as they have shown to be modified in tumor cells. Specifically, potential markers found in urine included modified nucleosides, sarcosine, creatinine, or acetylglutamine [26,28]. However, the measurement of modified nucleosides levels have not shown to be reproducible or robust and sarcosine has also shown to fail in prostate cancer detection [29].…”

Section: Introductionmentioning

confidence: 99%

Human sweat metabolomics for lung cancer screening

et al. 2015

View full text Add to dashboard Cite

Sweat is one of the less employed biofluids for discovery of markers in spite of its increased application in medicine for detection of drugs or for diagnostic of cystic fibrosis. In this research, human sweat was used as clinical sample to develop a screening tool for lung cancer, which is the carcinogenic disease with the highest mortality rate owing to the advanced stage at which it is usually detected. In this context, a method based on the metabolite analysis of sweat to discriminate between patients with lung cancer versus smokers as control individuals is proposed. The capability of the metabolites identified in sweat to discriminate between both groups of individuals was studied and, among them, a trisaccharide phosphate presented the best independent performance in terms of the specificity/sensitivity pair (80 and 72.7%, respectively). Additionally, two panels of metabolites were configured using the PanelomiX tool as an attempt to reduce false negatives (at least 80% specificity) and false positives (at least 80% sensitivity). The first panel (80% specificity and 69% sensitivity) was composed by suberic acid, a tetrahexose, and a trihexose, while the second panel (69% specificity and 80% sensitivity) included nonanedioic acid, a trihexose, and the monoglyceride MG(22:2). Thus, the combination of the five metabolites led to a single panel providing 80% specificity and 79% sensitivity, reducing the false positive and negative rates to almost 20%. The method was validated by estimation of within-day and between-days variability of the quantitative analysis of the five metabolites

show abstract

A Review of Applications of Metabolomics in Cancer

Cited by 244 publications

References 147 publications

Saliva diagnostics – Current views and directions

Saliva diagnostics – Current views and directions

Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling

Human sweat metabolomics for lung cancer screening

Contact Info

Product

Resources

About